ATE362985T1 - Apo-2 ligand - Google Patents

Apo-2 ligand

Info

Publication number
ATE362985T1
ATE362985T1 AT97903760T AT97903760T ATE362985T1 AT E362985 T1 ATE362985 T1 AT E362985T1 AT 97903760 T AT97903760 T AT 97903760T AT 97903760 T AT97903760 T AT 97903760T AT E362985 T1 ATE362985 T1 AT E362985T1
Authority
AT
Austria
Prior art keywords
ligand
apo
cytokine
antibodies
induce
Prior art date
Application number
AT97903760T
Other languages
English (en)
Inventor
Avi Ashkenazi
Anan Chuntharapai
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE362985T1 publication Critical patent/ATE362985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97903760T 1996-01-09 1997-01-08 Apo-2 ligand ATE362985T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/584,031 US6030945A (en) 1996-01-09 1996-01-09 Apo-2 ligand

Publications (1)

Publication Number Publication Date
ATE362985T1 true ATE362985T1 (de) 2007-06-15

Family

ID=24335618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97903760T ATE362985T1 (de) 1996-01-09 1997-01-08 Apo-2 ligand

Country Status (12)

Country Link
US (1) US6030945A (de)
EP (3) EP1734122A3 (de)
JP (4) JP2001510321A (de)
AT (1) ATE362985T1 (de)
AU (1) AU729279B2 (de)
CA (2) CA2241572C (de)
DE (1) DE69737747T2 (de)
DK (1) DK0873407T3 (de)
ES (1) ES2287948T3 (de)
IL (3) IL125168A0 (de)
PT (1) PT873407E (de)
WO (1) WO1997025428A1 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US20040048340A1 (en) * 1996-03-14 2004-03-11 Human Genome Sciences, Inc. Apoptosis inducing molecule I
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
IL133122A0 (en) * 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
JP4303883B2 (ja) 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
EP1021542B1 (de) * 1997-10-10 2009-03-04 Genentech, Inc. Apo-3 ligand
JP2002508962A (ja) * 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
AU2338299A (en) 1998-01-26 1999-08-09 Genentech Inc. Antibodies to death receptor 4 (dr4) and uses thereof
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
WO1999048527A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
EP1941905A1 (de) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Liganden-Anti-HER-2-Antikörper-Synergismus
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
ATE443723T1 (de) * 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
WO2000031254A2 (en) * 1998-11-23 2000-06-02 Amgen, Inc. Apoptosis-inducing factor
US6773911B1 (en) 1998-11-23 2004-08-10 Amgen Canada Inc. Apoptosis-inducing factor
CA2365913C (en) 1999-04-12 2015-03-03 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
EP1873244A3 (de) * 1999-06-02 2008-04-02 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
EP1658859A1 (de) * 1999-06-09 2006-05-24 Genentech, Inc. APO-2L Rezeptor-Agonist und CPT-11 Synergie-Effekt
CN101633692A (zh) * 1999-06-28 2010-01-27 杰南技术公司 利用二价金属离子制备Apo-2配体的方法
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
US6900185B1 (en) * 2000-04-12 2005-05-31 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
DE60136816D1 (de) * 2000-07-27 2009-01-15 Genentech Inc Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
AU2002228772B2 (en) * 2000-11-02 2005-12-08 Sloan Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors
JP2002306170A (ja) * 2001-04-06 2002-10-22 Jenokkusu Soyaku Kenkyusho:Kk アレルギー性疾患の検査方法
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
EP1409544B1 (de) 2001-07-03 2009-06-17 Genentech, Inc. Humane dr4-antikörper und deren anwendungen
EP1501866A4 (de) * 2001-10-02 2006-02-08 Genentech Inc Varianten des liganden apo-2 und verwendungen davon
EP1450847B1 (de) 2001-11-13 2010-09-29 Genentech, Inc. Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
US7842668B1 (en) 2001-11-13 2010-11-30 Genentech, Inc. Apo-2 ligand/trail formulations
EP2500032A1 (de) 2002-06-24 2012-09-19 Genentech, Inc. APO-2-Liganden-/Trailvarianten und Verwendungen dafür
JP2006506985A (ja) * 2002-10-30 2006-03-02 ファイザー・プロダクツ・インク コンパニオンアニマルのガンを診断および治療するための方法および組成物
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
BRPI0507233B8 (pt) 2004-03-11 2021-05-25 Genentech Inc processo para a produção de um polipeptídeo heterólogo em e. coli
US20080274955A1 (en) * 2004-04-13 2008-11-06 Kyungpook National University Industry Academic Cooperation Foundation Novel Use of a Polypeptide Comprising Fas-1 Domain
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
AU2012200601B2 (en) * 2004-08-06 2012-10-11 Genentech, Inc. Assays and methods using biomarkers
MX2007001469A (es) 2004-08-06 2007-03-26 Genentech Inc Ensayos y metodos que utilizan biomarcadores.
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008513367A (ja) * 2004-09-08 2008-05-01 ジェネンテック・インコーポレーテッド デスレセプターリガンド及びｃｄ２０抗体の使用方法
US20090175854A1 (en) * 2004-09-08 2009-07-09 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
US20060188498A1 (en) 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US8999289B2 (en) 2005-03-22 2015-04-07 President And Fellows Of Harvard College Treatment of protein degradation disorders
CN101287990B (zh) 2005-08-16 2012-07-04 健泰科生物技术公司 通过检测细胞/组织中galnac-t14的表达判定对apo2l/trail的凋亡敏感性
ES2618543T3 (es) 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
WO2007095584A2 (en) 2006-02-14 2007-08-23 The President And Fellows Of Harvard College Histone Deacetylase Inhibitors
US8222423B2 (en) 2006-02-14 2012-07-17 Dana-Farber Cancer Institute, Inc. Bifunctional histone deacetylase inhibitors
US8304451B2 (en) * 2006-05-03 2012-11-06 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
AU2009274549B2 (en) * 2008-07-23 2014-05-01 Dana-Farber Cancer Institute, Inc. Deacetylase inhibitors and uses thereof
AU2009319864A1 (en) 2008-11-25 2011-07-14 Biogen Idec Ma Inc. Use of DR6 and P75 antagonists to promote survival of cells of the nervous system
MX2011012623A (es) * 2009-05-27 2011-12-14 Glaxosmithkline Biolog Sa Construcciones de casb7439.
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
ES2356880B8 (es) * 2009-08-21 2012-10-30 Universidad De Zaragoza Liposomas recubiertos con el dominio extracelular de la proteína apo2l/trail.
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
EP2704735A1 (de) 2011-05-03 2014-03-12 Genentech, Inc. Vaskuläre disruptoren und ihre verwendung
US9289468B2 (en) 2011-09-16 2016-03-22 Beijing Sunbio Biotech Co. Ltd. Fusion protein comprising circularly permuted form of trail/Apo2L, coding gene and use thereof
BR112016017660B1 (pt) 2014-02-27 2022-04-19 F. Hoffmann-La Roche Ag Método para a produção de uma glicoproteína recombinante
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
WO2020193718A1 (en) * 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
JP2023521236A (ja) 2020-04-15 2023-05-23 ジェネンテック， インコーポレイテッド 接種前の培養培地の処理方法
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
IL302740A (en) 2020-11-16 2023-07-01 Hoffmann La Roche Fab high mannose glycoforms

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (de) *
US3691016A (en) * 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) * 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) * 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) * 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) * 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4206226A (en) * 1977-08-29 1980-06-03 The United States Of America As Represented By The Department Of Health, Education And Welfare Use of 4-carboxy-phthalato-(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof in alleviating L1210 murine leukemia
FR2413974A1 (fr) * 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4229537A (en) * 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) * 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU2353384A (en) * 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) * 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (de) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987005330A1 (en) * 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5010182A (en) * 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) * 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
GB8724885D0 (en) * 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
EP0321196A3 (de) * 1987-12-18 1990-07-18 Mycogen Plant Science, Inc. Transkriptionsaktivator des 780 T-DNA-Gens
KR0154872B1 (ko) * 1987-12-21 1998-10-15 로버트 에이. 아미테이지 발아하는 식물종자의 아크로박테리움 매개된 형질전환
AU4005289A (en) * 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
FR2646437B1 (fr) * 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
DK168302B1 (da) * 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
EP0939121B2 (de) * 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
EP0502036B1 (de) * 1989-11-22 1995-12-20 Genentech, Inc. Latenz assoziierte peptide und deren verwendung
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992020373A1 (en) * 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) * 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2140280A1 (en) * 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
ATE183513T1 (de) * 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
WO1995010540A1 (en) * 1993-10-14 1995-04-20 Immunex Corporation Fas antagonists and uses thereof
WO1995011301A1 (en) * 1993-10-19 1995-04-27 The Regents Of The University Of Michigan P53-mediated apoptosis
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
DK1666591T3 (da) * 1995-06-29 2011-05-23 Immunex Corp Cytokin der inducerer apoptose
AU5711196A (en) * 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997046686A2 (en) * 1996-06-07 1997-12-11 Amgen Inc. Tumor necrosis factor-related polypeptide

Also Published As

Publication number Publication date
CA2241572A1 (en) 1997-07-17
EP1889915A1 (de) 2008-02-20
US6030945A (en) 2000-02-29
IL125168A0 (en) 1999-01-26
JP2008308502A (ja) 2008-12-25
EP1734122A2 (de) 2006-12-20
JP2005237370A (ja) 2005-09-08
AU729279B2 (en) 2001-02-01
EP1734122A3 (de) 2007-07-11
WO1997025428A1 (en) 1997-07-17
ES2287948T3 (es) 2007-12-16
DK0873407T3 (da) 2007-09-24
DE69737747T2 (de) 2008-02-14
DE69737747D1 (de) 2007-07-05
PT873407E (pt) 2007-09-04
CA2666263A1 (en) 1997-07-17
AU1824897A (en) 1997-08-01
HK1018961A1 (en) 2000-01-14
IL125168A (en) 2011-04-28
CA2241572C (en) 2009-08-11
EP0873407A1 (de) 1998-10-28
JP2001510321A (ja) 2001-07-31
IL193752A0 (en) 2011-08-01
EP0873407B1 (de) 2007-05-23
JP2007169280A (ja) 2007-07-05

Similar Documents

Publication Publication Date Title
ATE362985T1 (de) Apo-2 ligand
DK1045906T3 (da) APO-2-ligand
DE69838249D1 (de) Anti-apo-2 antikörper
IS6322A (is) Viðtaki APRIL (BCMA) og notkun hans
PL337314A1 (en) Imidazolyl-cyclic acetals
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
DE3575769D1 (de) Kraftwerk zur ausnutzung von waermeenergie des meeres.
DK1009817T3 (da) RTD-receptor
ES2146243T3 (es) Inhibidores de tnf.
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
ATE236983T1 (de) Durch zelldichte stimulierte protein-tyrosin- phosphatasen
IT8521842A0 (it) Composizione refrattaria eprocedimento per ottenerla.
IT8521771A0 (it) Dispersione di olio in acqua per uso agricolo.
PT84189A (pt) Improvements relating to solid fuel briquettes
IT1194823B (it) Composizione di rivestimento di elettrodeposito catodico e procedimento per ottenerla
IT8419465A0 (it) Dispersione di carbone in acqua.
NO863713D0 (no) Fremgangsmaate for omdannelse av oksygenater til alkylerte flytende hydrokarboner.
SATO Development of PC Precast Slab Pavement Connected with Horn-Joints
IT8419466A0 (it) Dispersione di carbone in acqua.
IT1197846B (it) Coltivazione in serre di tipo idroeroponico
IT8521286U1 (it) Stufa, per il riscaldamento di ambienti, comprendente mezzi per ottenere elevati rendimenti.
KR850005112U (ko) 농산폐기물을 연료로 이용하는 흙벽돌 난로
IT1175225B (it) Procedimento per ridurre la quantita' di combustibile necessaria per cuocere i laterizi nelle fornaci

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0873407

Country of ref document: EP